On August 2, Advaxis, Inc. (NASDAQ: ADXS) and Amgen announced an agreement for the development and commercialization of Advaxis’ novel cancer immunotherapy treatment, providing Advaxis with milestone payments of up to $475 million in addition to royalties. Advaxis is developing a number of other immunotherapies for cancer that have also shown great promise. So how does this involve JMJ?
In 2011, we saw the promise of a then-small OTC company’s research. Over the next few years, JMJ invested millions in Advaxis, through good times and bad, helping provide the company with the runway and resources necessary to further develop their therapies, uplist to NASDAQ, and ultimately achieve milestones like this agreement with Amgen. In the near future, their novel treatments may be saving and extending people’s lives worldwide.
If your company or client is looking for a financial partner that is willing to take the risk of making unsecured investments early on, and to stand by the company through thick and thin, look no further than JMJ Financial.
Selected investments are highlighted below:
$500,000: an innovative manufacturer of lithium-ion battery solutions for a variety of industrial and consumer markets.
$585,000: an alternative energy manufacturing company specializing in the conversion of bio-organic materials.
$200,000: an oil and gas exploration and development company.
$1,000,000: a developer of electrically conductive hybrid plastics used in the production of industrial, commercial, and consumer products.
$500,000: a healthcare company that operates medical clinics offering expert care in the treatment and recovery of substance abuse issues.
$650,000: a bio-pharmaceutical company engaged in the development and commercialization of targeted immune therapies.